Asset Details
Do you wish to reserve the book?
Valproic acid-induced hyperammonemia with encephalopathy in adults: a meta-analysis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Valproic acid-induced hyperammonemia with encephalopathy in adults: a meta-analysis
Do you wish to request the book?
Valproic acid-induced hyperammonemia with encephalopathy in adults: a meta-analysis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Valproic acid-induced hyperammonemia with encephalopathy in adults: a meta-analysis
2025
Overview
Valproic acid, frequently prescribed for neurological and psychiatric disorders, can cause hyperammonemia (HA). This retrospective study aimed to investigate the association among the basic characteristics, comorbidities, co-medications, and risk of HA in patients receiving valproic acid.
We compared groups with and without HA using data collected from the medical records of adults undergoing valproic acid monitoring between January 1, 2019, and December 31, 2021. We conducted a multivariable logistic regression analysis to explore the risk factors for HA and a comprehensive systematic literature review to identify factors significantly associated with valproic acid-related HA.
In total, 247 patients were included, with 37 in the HA group (serum ammonia level > 150 mcg/dL); almost all of them eventually developed hyperammonemic encephalopathy (HE). Multivariable logistic regression analysis revealed that valproic acid levels (odds ratio (OR): 1.01, 95% confidence interval (CI): 0.99 - 1.03), epilepsy (OR: 3.82, 95% CI: 1.52 - 9.62), congestive heart failure (OR: 32.3, 95% CI: 4.09 - 255.4), and concomitant phenytoin use (OR: 6.4, 95% CI: 1.07 - 38.12) are independently associated with HA development during valproic acid therapy. Our data and those of previous studies demonstrate significant associations of valproic acid-related HA with concomitant phenytoin and topiramate use; serum valproic acid concentrations were also significantly positively correlated with serum ammonia levels.
The results suggest that serum ammonia and valproic acid levels should be monitored during valproic acid treatment, particularly with concurrent use of phenytoin or topiramate, to prevent further deterioration of HE.
Publisher
Dustri - Verlag Dr. Karl Feistle GmbH & Co. KG
Subject
/ Adult
/ Aged
/ Ammonia
/ Anticonvulsants - adverse effects
/ Brain Diseases - chemically induced
/ Brain Diseases - epidemiology
/ Female
/ Humans
/ Hyperammonemia - chemically induced
/ Hyperammonemia - epidemiology
/ Male
/ Neurotoxicity Syndromes - blood
/ Neurotoxicity Syndromes - diagnosis
/ Neurotoxicity Syndromes - epidemiology
